Acknowledgement
Supported by : National Research Foundation of Korea (NRF)
References
- Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-21. https://doi.org/10.3322/caac.20078
- American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018;41:S13-27. https://doi.org/10.2337/dc18-S002
- Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab 2011;96:1654-63. https://doi.org/10.1210/jc.2011-0585
- Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003;58:335-41. https://doi.org/10.1179/acb.2003.58.6.001
- O'Keefe JH Jr, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999;74:171-80. https://doi.org/10.4065/74.2.171
- Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38. https://doi.org/10.1002/jbt.10058
- World Health Organization. Diabetes. http://www.who.int/newsroom/fact-sheets/detail/diabetes. Accessed November 15, 2017.
- Lee JW, Kang HT, Lim HJ, Park B. Trends in diabetes prevalence among Korean adults based on Korean National Health and Nutrition Examination Surveys III-VI. Diabetes Res Clin Pract 2018;138:57-65. https://doi.org/10.1016/j.diabres.2018.01.013
- Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int 2014;2014:461917.
- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91. https://doi.org/10.1038/nrc1408
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33. https://doi.org/10.1126/science.1160809
- Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7:507-16. https://doi.org/10.1038/nrendo.2011.77
- Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 2010;6:444-53. https://doi.org/10.1038/nrendo.2010.93
- Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122:S185-92. https://doi.org/10.1161/CIRCULATIONAHA.109.931782
- Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 2013;380:73-81. https://doi.org/10.1007/s11010-013-1660-4
- Sayin O, Tokgoz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2014;27:479-84.
- Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) 2012;20:1394-402. https://doi.org/10.1038/oby.2012.31
- Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468-81. https://doi.org/10.1016/j.cmet.2008.10.011
- Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy 2016;117:100-5.
- Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci 2018;19:E1293. https://doi.org/10.3390/ijms19051293
- Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest 2016;39:747-54. https://doi.org/10.1007/s40618-016-0453-5
- Yildirim B, Celik O, Aydin S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol 2014;41:310-2.
- Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 2013;41:375-80.
- Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin- a novel biomarker of heart disease: a systematic review article. Iran J Public Health 2016;45:1568-76.
- Shahjouei S, Ansari S, Pourmotabbed T, Zand R. Potential roles of adropin in central nervous system: review of current literature. Front Mol Biosci 2016;3:25.
- Nergiz S, Altinkaya SO, Kurt Omurlu I, Yuksel H, Kucuk M, Demircan Sezer S. Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol 2015;31:730-5. https://doi.org/10.3109/09513590.2015.1065480
- Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40. https://doi.org/10.3390/nu5041218
- Pitha J, Kovar J, Blahova T. Fasting and nonfasting triglycerides in cardiovascular and other diseases. Physiol Res 2015;64 Suppl 3:S323-30.
- Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index [published online ahead of print April 17, 2018]. Endocr J. doi: 10.1507/endocrj.EJ18-0060.
- Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 2014;52:751-8.
- Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 2014;63:3242-52. https://doi.org/10.2337/db14-0388
- Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:159-91. https://doi.org/10.1146/annurev.physiol.68.033104.152158
- Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-51. https://doi.org/10.2119/2008-00058.Rabe
- Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008;35:321-6. https://doi.org/10.1016/S1673-8527(08)60047-8
- Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92. https://doi.org/10.1172/JCI29126
- Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-senitizing adipocyte-derived protein. Diabetes 2002;51:2734-41. https://doi.org/10.2337/diabetes.51.9.2734
- Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808. https://doi.org/10.1172/JCI200319246
- Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007;56:16-23. https://doi.org/10.2337/db06-1076